Editorial: Immunotherapy for NSCLC with oncogenic driver variants

• Yijia Du,
• Qian Chu,
• Yanyan Lou,
• Yong He,
• Hongbo Hu,
• Qipeng Hu,
• Meijuan Huang

Affiliations

Yijia Du

Thoracic Oncology Ward, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China

Qian Chu

Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Yanyan Lou

Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL, United States

Yong He

Department of Respiratory Medicine, Daping Hospital, Army Medical University, Chongqing, China

Hongbo Hu

Department of Rheumatology and Immunology, State Key Laboratory of Biotherapy and Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China

Qipeng Hu

Division of Pathogenesis of Virus Associated Tumors, German Cancer Research Centre Deutsches Krebsforschungszentrum(DKFZ), Heidelberg University, Heidelberg, Germany

Meijuan Huang

Thoracic Oncology Ward, Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, China